Conversely, in malignant settings, aberrant or sustained HO-1 activation can promote tumor progression by enhancing invasive behavior, facilitating immune evasion, and fostering therapy tolerance through oxidative-stress buffering and metabolic reprogramming [14]. Here, HMOX1 is linked to neoplasm.